Edition:
United Kingdom

Catalyst Pharmaceuticals Inc (CPRX.OQ)

CPRX.OQ on NASDAQ Stock Exchange Capital Market

6.27USD
21 Aug 2019
Change (% chg)

-- (--)
Prev Close
$6.27
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
463,043
52-wk High
$6.32
52-wk Low
$1.85

Select another date:

Wed, Jun 12 2019

Catalyst Pharma sues FDA over approval of cheaper rival drug

Catalyst Pharmaceuticals Inc, which has come under fire for the high price tag on its rare disease drug, on Wednesday sued the U.S. Food and Drug Administration to challenge the recent approval of a lower-cost rival drug.

UPDATE 2-Catalyst Pharma sues FDA over approval of cheaper rival drug

June 12 Catalyst Pharmaceuticals Inc, which has come under fire for the high price tag on its rare disease drug, on Wednesday sued the U.S. Food and Drug Administration to challenge the recent approval of a lower-cost rival drug.

Catalyst Pharma files lawsuit against U.S. FDA on Jacobus Pharma drug approval

June 12 Catalyst Pharmaceuticals Inc said on Wednesday it has filed a lawsuit against the U.S. Food and Drug Administration, challenging the recent approval of Jacobus Pharmaceutical Co's drug, Ruzurgi, for a rare neuromuscular disease.

UPDATE 1-U.S. Senator Sanders urges FDA to allow older versions of $375,000 drug

Feb 28 U.S. Senator Bernie Sanders this week urged regulators to allow pharmacies and manufacturers to resume distributing unbranded, lower-cost versions of a drug used to treat a rare neuromuscular disorder, according to a letter provided by his office to Reuters.

Select another date: